Tokushima University / Educator and Researcher Directory --- Minato, Masanori

Search:

Tokushima University ⟩ University Hospital ⟩ Clinical Division ⟩ Department of Internal Medicine ⟩ Nephrology ⟩

(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Masanori Tamaki, Taizo Inagaki, Masanori Minato, Eriko Shibata, Rika Nishioka, Satoshi Nishioka, Yukiko Matsubara, Masamitsu Sasaki, Motoyuki Tamaki, Masaharu Tamaki, Kazuhiro Hasegawa, Kojiro Nagai and Shu Wakino : Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study, Internal Medicine, 64, 9, 1303-1314, 2025. (Summary) Objective Roxadustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, increases the hemoglobin (Hb) levels in patients with chronic kidney disease (CKD). To date, limited clinical studies have focused on the excessive increase in the Hb levels in the early weeks after switching from erythropoiesis-stimulating agents (ESA) to roxadustat in adult non-dialysis patients. We conducted a retrospective study to examine whether early overshoot frequently occurs after switching to roxadustat. Methods This 8-week retrospective pilot study examined patients with anemic, non-dialyzed CKD who switched from ESA (darbepoetin or epoetin beta pegol) to roxadustat or continued ESA. The Hb levels >12.5 g/dL after starting our observation was defined as Hb overshoot. Patients: Twenty-three patients who switched to roxadustat (roxadustat group) and 63 who continued ESA (ESA group) were included. Results The baseline median estimated glomerular filtration rate and mean Hb levels were 15.7 mL/min/1.73 m² and 10.77 g/dL in roxadustat group and 15.2 mL/min/1.73 m² and 10.64 g/dL in ESA group, respectively. Eight patients (34.8%) in the roxadustat group and two patients (3.2%) in the ESA group had Hb overshoot within the 8-week visit [odds ratio: 20.2 (95% confidence interval 3.13-130.0, p<0.01) in the background adjusted model]. Among the patients with Hb overshoot in the roxadustat group, the Hb levels were maintained close to baseline 4 weeks after roxadustat discontinuation. A younger age and higher baseline Hb and Hct levels were risk factors for Hb overshoot. Conclusion Hb overshoot was frequently observed in patients switched to roxadustat. Clinicians should be aware of Hb overshoot and emphasize the importance of early Hb level checks. (Keyword) chronic kidney disease / real-world evidence / renal anemia / roxadustat (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.3773-24 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39370259 ● Summary page in Scopus @ Elsevier: 2-s2.0-105004022755 (DOI: 10.2169/internalmedicine.3773-24, PubMed: 39370259, Elsevier: Scopus)
2.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada and Shu Wakino : Ability of NAD and Sirt1 to epigenetically suppress albuminuria., Clinical and Experimental Nephrology, 28, 7, 599-607, 2024. (Summary) The time for diabetic nephropathy (DN) to progress from mild to severe is long. Thus, methods to continuously repress DN are required to exert long-lasting effects mediated through epigenetic regulation. In this study, we demonstrated the ability of nicotinamide adenine dinucleotide (NAD) and its metabolites to reduce albuminuria through Sirt1- or Nampt-dependent epigenetic regulation. We previously reported that proximal tubular Sirt1 was lowered before glomerular Sirt1. Repressed glomerular Sirt1 was found to epigenetically elevate Claudin-1. In addition, we reported that proximal tubular Nampt deficiency epigenetically augmented TIMP-1 levels in Sirt6-mediated pathways, leading to type-IV collagen deposition and diabetic fibrosis. Altogether, we propose that the Sirt1/Claudin-1 axis may be crucial in the onset of albuminuria at the early stages of DN and that the Nampt/Sirt6/TIMP-1 axis promotes diabetic fibrosis in the middle to late stages of DN. Finally, administration of NMN, an NAD precursor, epigenetically potentiates the regression of the onset of DN to maintain Sirt1 and repress Claudin-1 in podocytes, suggesting the potential use of NAD metabolites as epigenetic medications for DN. (Keyword) Animals / Humans / Albuminuria / Claudin-1 / cytokinesis / Diabetic Nephropathies / Epigenesis, Genetic / Fibrosis / Kidney Tubules, Proximal / Mice, Inbred C57BL / knockout mice / NAD / Nicotinamide Mononucleotide / Nicotinamide Phosphoribosyltransferase / Podocytes / Sirtuin 1 / Sirtuins / Tissue Inhibitor of Metalloproteinase-1 (Tokushima University Institutional Repository) ● Metadata: 2012209 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10157-024-02502-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38587753 ● Summary page in Scopus @ Elsevier: 2-s2.0-85189697626 ● Summary page in Scopus @ Elsevier: 2-s2.0-85196749614 (Tokushima University Institutional Repository: 2012209, DOI: 10.1007/s10157-024-02502-w, PubMed: 38587753, Elsevier: Scopus, Elsevier: Scopus)

Review, Commentary:

1.	Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Masanori Minato, Taizo Inagaki, 清水郁子, Sumiyo Yamaguchi, 宮上慎司, 多田美穂 and Shu Wakino : 特集糖尿病性腎症研究の最前線糖尿病性腎症の発症機序糖尿病性腎症におけるミトコンドリアの役割, Kidney and Dialysis, 96, 2, 159-164, Feb. 2024. (Tokushima University Institutional Repository) ● Metadata: 2012211 (Link to Publication Site) ● Publication site (DOI): 10.24479/kd.0000001187 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390299528381041664 ● Search Scopus @ Elsevier (DOI): 10.24479/kd.0000001187 (Tokushima University Institutional Repository: 2012211, DOI: 10.24479/kd.0000001187, CiNii: 1390299528381041664)

Proceeding of Domestic Conference:

1.	Masanori Tamaki, Taizo Inagaki, Masanori Minato, Eriko Shibata, Kazuhiro Hasegawa, 西岡聡, 佐々木正充, 湊淳, 一森敏弘, 山本修三, 田蒔正治 and Shu Wakino : 血漿交換と分子標的薬治療で救命し血液透析を継続しているTAFRO症候群の1例, 第55回徳島透析療法研究会, Nov. 2025.
2.	Sumiyo Yamaguchi, Taizo Inagaki, 沖成千尋, 平田彩乃, 多田美穂, Masanori Minato, Eriko Shibata, Masanori Tamaki, Kazuhiro Hasegawa and Shu Wakino : マルチキナーゼ阻害薬投与によりlupus like nephrotisを発症した1例, 第131回日本内科学会四国地方会, Dec. 2024.
3.	Shu Wakino, 柴田理恵子, Kazuhiro Hasegawa, Masanori Tamaki, Masanori Minato, Taizo Inagaki, 宮上慎司, 多田美穂 and Ichiro Hashimoto : 皮膚虚血・潰瘍病変患者における血中亜鉛濃度の意義, 第53回徳島透析療法研究会, Dec. 2023.
4.	Shu Wakino, Eriko Shibata, Masanori Minato, Ikuko Shimizu and Kazuhiro Hasegawa : 皮膚潰瘍病変患者における血中亜鉛濃度の意義, Journal of Japanese Society for Dialysis Therapy, 56, Suppl.1, 566, May 2023.
5.	Masanori Minato, Ikuko Shimizu, Masanori Tamaki, Kazuhiro Hasegawa and Shu Wakino : 長時間のAPDにより至適透析を得た重度の精神発達遅滞を有する一例, Journal of Japanese Society for Dialysis Therapy, 56, Suppl.1, 563, 2023.
6.	Masanori Tamaki, 宮上慎司, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : ロキサデュスタット投与後に奇異性脳塞栓を発症した1例, Japanese Journal of Nephrology, 64, 6-W, 719, Oct. 2022.
7.	宮上慎司, Masanori Tamaki, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : コロナウィルスワクチン後発症した悪性腎硬化症の一例, Japanese Journal of Nephrology, 64, 6-W, 719, Oct. 2022.
8.	Masanori Tamaki, 宮上慎司, Ikuko Shimizu, 山口純代, Masanori Minato, Sayo Ueda, Eriko Shibata, Motoyuki Tamaki, Motoyuki Tamaki, Kazuhiro Hasegawa, Kojiro Nagai and Shu Wakino : ESAからロキサデュスタットへ切り替えた保存期CKD症例の解析, Japanese Journal of Nephrology, 64, 3, 257, May 2022.
9.	Sayo Ueda, Eriko Shibata, Masanori Tamaki, Masanori Minato, 岩城真帆, Ikuko Shimizu, Sumiyo Yamaguchi, 宮上慎司, Kazuhiro Hasegawa and Shu Wakino : 急性間質性腎炎を認めた敗血症性AKIの症例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 507, May 2022.
10.	Masanori Tamaki, 宮上慎司, 岩城真帆, Ikuko Shimizu, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kojiro Nagai, Kazuhiro Hasegawa and Shu Wakino : 腹膜透析導入後に膵癌を発症した1例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 631, May 2022.
11.	Ikuko Shimizu, Masanori Tamaki, 宮上慎司, Sumiyo Yamaguchi, Masanori Minato, Sayo Ueda, Eriko Shibata, Kazuhiro Hasegawa and Shu Wakino : 慢性大動脈解離に伴う慢性DICのため腎代替療法導入に苦慮した1例, Journal of Japanese Society for Dialysis Therapy, 55, Suppl.1, 663, May 2022.
12.	Sumiyo Yamaguchi, Masanori Tamaki, Ikuko Shimizu, Shinji Miyakami, Masanori Minato, Sayo Ueda, Eriko Shibata, Kojiro Nagai and Shu Wakino : ペメトレキセドによる尿細管間質性腎炎の一例, 第51回日本腎臓学会西部学術集会, Oct. 2021.